Human placental blood is a source of haemopoietic stem cells both for transplantation [1] [2] [3] [4] and gene therapy applications. 5 However, considerable interest in developing methods for expanding cord blood stem cell numbers in vitro [6] [7] [8] [9] [10] [11] [12] [13] [14] has been stimulated by the fact that a single cord blood collection may not be sufficient to guarantee engraftment of adult allogeneic recipients. The cultures are traditionally performed in a medium containing fetal calf serum (FCS) but to utilise expanded cells in clinical practice, 'good manufacturing practice' (GMP) standards and serum-free (SF) conditions are required. In particular, FCS must be excluded from the medium because it may contain allergenic substances and transmissible infections. Furthermore, pooled human serum (HS) should be excluded to eliminate variables linked to individual donors. 15, 16 In this study we investigated how CD34
+ placental blood cells grow in SF conditions in the presence of haemopoietic growth factors (flt3 ligand (FL), thrombopoietin (TPO), kit ligand (KL) Ϯ interleukin 6 (IL6) ) but in the absence of stroma. At different times, total cell, CD34
+ , CFC and LTC-IC content was measured. Moreover, after 14 days expansion the in vivo repopulating capacity of cells was determined. The results were compared with those obtained in the presence of HS or FCS.
Materials and methods

CD34
+ cell purification Twenty-four placental blood samples were obtained, with the informed consent of the mother, from full-term deliveries. CD34 + cells were isolated from the placental blood mononuclear fraction using a MiniMACS CD34 isolation kit (Miltenyi Biotech, Bisley, UK) according to the manu-Bone Marrow Transplantation facturer's instructions. The efficiency of purification was verified by flow cytometry counterstaining with an anti-CD34-phycoerythrin (PE) antibody (HPCA-2; Becton Dickinson, San Jose, CA, USA).
Liquid cultures
A total of 2 ϫ 10 4 initial CD34 + cells were cultured in quadruplicate in flat bottomed 24-well plates in 1 ml of Iscove's modified Dulbecco's medium (IMDM; GIBCO BRL, Grand Island, NY, USA) supplemented with 10% FCS (Hyclone, Logan, UT, USA), 10% HS or SF conditions containing bovine serum albumin (BSA; Sigma Chemical Co, Milan, Italy) 20 mg/ml, insulin 10 g/ml and transferrin 200 l/ml (BIT; Stem Cell Technologies, British Columbia, Canada). The following growth factors were added: rhFL (50 ng/ml) + rhTPO (20 ng/ml) + rhKL (50 ng/ml) (three GF combination); rhFL (50 ng/ml) + rhTPO (20 ng/ml) + rhKL (50 ng/ml) + rhIL6 (10 ng/ml) (four GF combination). Each growth factor was added twice a week to the cultures. The wells were maintained at 37°C during culture. At the initiation of culture the number of CFC content in 1 ml was determined by triplicate plasma clot assays. Each week half of the medium was removed and replaced with fresh medium and growth factors. The removed cells were counted and assayed for CFC, LTC-IC content and analysed for CD34 + phenotype. For NOD/SCID mice repopulating experiments, CD34
+ were grown both in 25 or 75 cm 2 flasks with IMDM or X-vivo 15 (Bio-Whittaker, Walkersville, MD, USA) medium for 14 days. Weekly cultures were not demipopulated but medium was added in order to double the volume. Aliquots were removed from the medium and the cells were counted and analysed for CD34 + , CFC and LTC-IC content.
Recombinant human cytokines
Recombinant human (rh) kit-ligand (rhKL) and recombinant human thrombopoietin (rhTPO) were generous gifts from Amgen (Thousand Oaks, CA, USA), recombinant human granulocyte colony-stimulating factor (rhG-CSF), recombinant human interleukin-3 (rhIL-3) and recombinant human interleukin-6 (rhIL-6) were from Sandoz (Basel, Switzerland), recombinant human Flt3 ligand was kindly provided by SD Lyman (Immunex Corp, Seattle, WA, USA), recombinant human erythropoietin (rhEPO, Eprex) was from Cilag (Milan, Italy).
Flow cytometric analysis
Initial and cultured cells were evaluated for the expression of CD34 antigen. Cells were labelled with monoclonal antibodies anti-CD34 PE (HPCA-2; Becton Dickinson, San Jose, CA, USA). Cells were enumerated according to ISH-AGE guidelines. 17 Labelling lasted for 30 min in the dark, at 4°C. Then, cells were washed twice in phosphate-buffered saline (PBS) + 1% BSA and analysed with a FACScan flow cytometer (Becton Dickinson). At least 5000 events were acquired for each analysis. When fluorescent cells represented only a minority of the total population, many more events were considered (20 000). Analysis was performed with Cell Quest software (Becton Dickinson).
Haemopoietic cell cultures
Assays for CFC (CFU-GM, BFU-E, CFU-GEMM, CFUMeg) were performed as follows. For CFU-GM 1 ϫ 10 3 initial CD34
+ cells and suitable aliquots of liquid culture were cultured in four dishes per point in 3% agar, 15% FCS in IMDM. For CFU-Meg the same number of cells was cultured in plasma clot assays (four dishes per point). For BFU-E and CFU-GEMM the same number of cells was cultured in 1.3% methylcellulose (Fluka, Chemika Biochemika, Buchs, Switzerland) and IMDM containing 30% FCS at 37°C in a humidified atmosphere at 5% CO 2 in air. Colony scoring was performed on day 12 for CFU-Meg (at the immunofluorescent microscope after staining with a FITC (fluorescein-isothiocyanate)-conjugated anti-human GPIIb/IIIa antibody) and on day 14 for CFU-GM, BFU-E and CFU-GEMM. To sustain colony formation several growth factors were added: for BFU-E and CFU-GEMM, rhIL-3 (20 ng/ml), rhGM-CSF (10 ng/ml), rhEPO (3 U/ml) and rhKL (50 ng/ml) were added. For CFU-GM, rhIL-3 (20 ng/ml), rhGM-CSF (20 ng/ml) and rhKL (50 ng/ml) were added. For CFU-Meg, rhIL-3 (5 ng/ml) was the only growth factor added.
Long-term culture initiating cell cultures
The LTC-IC content of the cell suspension was determined by limiting dilution as previously described. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In short, 10 to 1000 initial CD34
+ cells or suitable aliquots during liquid cultures were washed and plated on pre-established bone marrow stroma as previously described. Cultures were maintained for 5 to 6 weeks at 37°C after which cells were harvested and seeded in a methylcellulose medium with 30% FCS, rhEPO (3 U/ml), rhKL (50 ng/ml), rhIL-3 (20 ng/ml), rhGM-CSF (20 ng/ml) and rhG-CSF (20 ng/ml). These cultures were incubated at 37°C at 5% CO 2 in air. The LTC-IC number was obtained by CFC output number in limiting dilution assay.
Bone marrow stroma
Human bone marrow was obtained by aspiration from the posterior iliac crests of healthy bone marrow donors, after informed consent. The mononuclear fraction was isolated using Ficoll-Hypaque (Nyegaard, Oslo, Norway) density centrifugation. In short, cells were seeded at 10 ϫ 10 6 /cm 2 in 25 cm 2 flasks in the presence of 12.5% FCS, 12.5% horse serum (Hyclone), 5 ϫ 10 −5 m 2-mercaptoethanol (Sigma, St Louis, MO, USA), 1 ϫ 10 −6 m hydrocortisone (Sigma) and penicillin/streptomycin. The medium was replaced twice weekly until confluence. Later, LTC-IC cultures were grown on a mixed murine fibroblastoid cell line (M210B4 and SL/SL) engineered to produce KL + IL3 + G-CSF.
Animals
Twenty NOD/Ltsz scid/scid (NOD/SCID) mice were obtained from Charles River Italia (Calco, Italy) and main-tained in the animal facilities at CIOS (Turin, Italy). All the animals were handled under sterile conditions and maintained in microisolator cages. The mice to be injected were exposed at 6-8 weeks of age to 350 cGy of total body irradiation with a 137 Cs source. Within 24 h the mice were injected with placental expanded cells with a single intravenous injection. The mice were killed 5-6 weeks later. Controls were transplanted with 30 000 CD34 + nonexpanded cells.
Analysis of human cells in murine tissue
Bone marrow cells were flushed from femurs and tibias of each mouse using a syringe and a 26-gauge needle. Cells were resuspended at 2 ϫ 10 6 cells/ml in Hank's balanced salt solution (HBSS; GIBCP BRL) containing 0.1% BSA and 0.01% sodium azide and incubated with mouse IgG (Fluka, Chemika Biochemika) and 5% human serum to block non-specific binding. The cells were then washed with PBS and incubated for 20 min with an anti-human CD45 monoclonal antibody, and simultaneously stained with an anti-human CD34, CD19, CD3, Glyco A and CD33 monoclonal antibodies (Becton Dickinson). Some cells in each condition were incubated with irrelevant monoclonal antibodies conjugated FITC or PE to exclude non-specific binding. Cells from unmanipulated mice were also stained with each monoclonal antibody used to test human engraftment. Only levels of fluorescence that excluded 99.9% of these negative controls were considered as specific.
Statistical analysis
Results are expressed as medians. A single hit was applied for LDA Poisson statistics. The frequency of LTC-IC in the cell suspension was calculated using a maximum likelihood estimator. Statistical differences among groups were calculated by Student's t-test as per P Ͻ 0.05.
Results
Ex vivo expansion of human placental CD34
+ cells
In an effort to induce long-term proliferation and amplification of primitive haemopoietic progenitors contained in CD34 + placental cells, stroma-free suspension cultures stimulated by the early acting cytokines FL, TPO, KL, and Ϯ IL6 were set-up. These growth factors were used with three different media (SF medium and serum-replete medium (HS and FCS)) in order to identify the influence of serum on cell growth.
Total cell number and CD34
+ output: The cell and CD34 (Figure 1a, b) . Table  1 shows phenotypic analysis of the three growth factor combination in a serum-free condition of placental blood CD34 + expansion after 14 days' culture.
for FCS after 8 weeks of culture
CFC and LTC-ICs output:
CFC expansion was similar in all culture conditions (Figure 1c) . The marginally lower output of CFC in SF conditions was not significant. LTC-IC behave rather differently since their number continued to increase in the presence of serum up to the 8th week of culture, whereas in a SF condition their number declined after the 6th week of culture (Figure 1d ). IL6 did not sig- (Figure 2a, b, c, d ). 19 
Analysis of NOD/SCID mice repopulating cell expansion in different medium
To investigate NOD/SCID mice repopulating cell expansion, groups of sublethally irradiated NOD/SCID mice were injected with CD34 + expanded cells. In these series of experiments the four growth factor combination was used and two different media (IMDM and X-vivo 15) were compared. Cells were expanded for 14 days and then injected into NOD/SCID mice. Controls were transplanted with 30 000 non-expanded cells. Six to 8 weeks later, bone marrow and spleen cells of animals that had been killed were assessed for human haemopoietic engraftment. As reported in Table 2 , higher levels of human engraftment in cultures containing HS (33%) or FCS (65%) were found. Nevertheless, SF cultured cells were also able to engraft both marrow and spleen in all animals. In particular, engraftment was higher with IMDM (up to 30% of human engraftment as a median of three experiments, range from 20 to 47%) than with X-vivo 15 medium (8.4%, range from 5.3 to 11%). Interestingly, higher marrow engraftment correlates with spleen engraftment in all conditions and all haemopoietic lineages were found among murine tissues. Characteristically, there was higher myeloid cell engraftment in marrow and lymphoid cells in spleen in all conditions analysed. Human CD34 + cells were found in both marrow and spleen cells. Higher CD34
+ cell engraftment was found with FCSreplete medium (4.8%). Once again, the SF condition also ensured CD34
+ cell engraftment (3.6% and 1.8% with IMDM or X-vivo 15, respectively). Unexpectedly, human cell engraftment did correlate with CFC but not with the LTC-IC content. In control mice human engraftment was very low (0-1.2%).
Discussion
The ability to expand haemopoietic cells under conditions that allow the retention of their functional characteristics when reinfused holds great promise. However, optimal defined conditions for human haemopoietic stem cell expansion need to be carefully developed. Our group recently reported in vitro and in vivo expansion of placental CD34
+ cells cultured with FL+TPO Ϯ KL Ϯ IL6 in a serum-replete medium, demonstrating that expansion for 4 to 10 weeks involved NOD/SCID mice repopulating cells. 9, 10 Since SF conditions are essential for clinical development, the present experiments were planned.
In the present study, CD34 + placental blood cells gave rise to an up to 90-fold increase of CFCs when cultured for 8 weeks in SF medium added to FL, TPO and KL. Furthermore, CD34
+ cells were expanded up to 50-fold over the initial seeding level. These data are not significantly different from those obtained in the presence of FCS, and are consistent with previous studies using long-term ex vivo culture of human cells in serum-replete media. 7 Therefore, the data support the feasibility of using SF medium in such studies. The kinetics of LTC-IC amplification were comparable among samples cultured with SF medium and serum-replete medium until the 6th week of culture, after which, however, a decline was observed. IL-6 did not significantly improve the cell, CFC and CD34 + expansion in our culture system, neither did it change LTC-IC outcome. Given the mixed in vitro results where LTC-IC declined in SF conditions, it became relevant to assess whether the in vivo repopulating capacity of NOD/SCID mice was maintained. Our data indicate that CD34 + cells cultured in the presence of FL, TPO, KL and IL-6 for up to 14 days engraft 100% of the irradiated mice. These data suggest that SF culture conditions can support both short-term and longterm marrow repopulating cells. These results demonstrate unequivocally that human haemopoietic stem cell activity assessed by their ability to regenerate lymphoid and myeloid progeny after 6 to 8 weeks in irradiated NOD/SCID mice is not inevitably or irreversibly lost when cells are activated mitogenically with soluble growth factors. 20 In addition, our findings show that most, if not all, of the stem cells present in the CD34 + fraction of human placental blood can be stimulated to proliferate rapidly in vitro by this growth factor combination. 21 Another interesting point is the discrepant loss rate we observed in LTC- IC and in vivo repopulating activities. However, other examples of a dissociation in LTC-IC and function in murine cells have been reported, indicative of differences in the molecular mechanisms required for primitive cells to be detected in these two assays. 15, 20, 21 Taken together, these findings confirm the concept of a significant persisting population of expanded transplantable stem cells in cultures of human placental blood cells stimulated by FL, TPO, KL Ϯ IL6.
The demonstration that SF cultures support a significant expansion of progenitor cells might represent an important alternative to the use of serum and provides a basis for further studies on the transplantation of human haemopoietic expanded stem/progenitor cells.
